Bevacizumab, when combined with monoclonal antibodies such as atezolizumab, has been confirmed as a potential therapy for non-squamous NSCLC with higher PD-L1 expression (≥50%) but without EGFR/ALK/ROS1 mutations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.